APA (7th ed.) Citation

Isambert, N., Delord, J., Soria, J., Hollebecque, A., Gomez-Roca, C., Purcea, D., . . . Fumoleau, P. (2015). Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer--results of a first-in-man dose-escalation study with a fixed-dose extension phase. Annals of Oncology, 26(5), 1005. https://doi.org/10.1093/annonc/mdv031

Chicago Style (17th ed.) Citation

Isambert, N., J.-P Delord, J.-C Soria, A. Hollebecque, C. Gomez-Roca, D. Purcea, E. Rouits, R. Belli, and P. Fumoleau. "Debio0932, a Second-generation Oral Heat Shock Protein (HSP) Inhibitor, in Patients with Advanced Cancer--results of a First-in-man Dose-escalation Study with a Fixed-dose Extension Phase." Annals of Oncology 26, no. 5 (2015): 1005. https://doi.org/10.1093/annonc/mdv031.

MLA (9th ed.) Citation

Isambert, N., et al. "Debio0932, a Second-generation Oral Heat Shock Protein (HSP) Inhibitor, in Patients with Advanced Cancer--results of a First-in-man Dose-escalation Study with a Fixed-dose Extension Phase." Annals of Oncology, vol. 26, no. 5, 2015, p. 1005, https://doi.org/10.1093/annonc/mdv031.